User menu

Once daily MMX mesalazine for the treatment of mild-to-moderate ulcerative colitis: a phase II, dose-ranging study

Bibliographic reference D'Haens, G. ; Dewit, Olivier ; Hommes, D. ; Engels, L. ; Baert, F. ; et. al. Once daily MMX mesalazine for the treatment of mild-to-moderate ulcerative colitis: a phase II, dose-ranging study. In: Alimentary Pharmacology and Therapeutics, Vol. 24, no. 7, p. 1087-1097 (2006)
Permanent URL
  1. Ardizzone S, Ulcerative Colitis
  2. Sutherland L, Cochrane Database Syst Rev, CD000544 (2002)
  3. Sutherland L, Cochrane Database Syst Rev, CD000543 (2003)
  4. Kane Sunanda, Huo Dezheng, Aikens James, Hanauer Stephen, Medication nonadherence and the outcomes of patients with quiescent ulcerative colitis, 10.1016/s0002-9343(02)01383-9
  5. van Hees PA, J Clin Gastroenterol, 4, 333 (1982)
  6. Kane Sunanda V., Cohen Russell D., Aikens James E., Hanauer Stephen B., Prevalence of nonadherence with maintenance mesalamine in quiescent ulcerative colitis, 10.1111/j.1572-0241.2001.04683.x
  7. Levy Rona L., Feld Andrew D., Increasing patient adherence to gastroenterology treatment and prevention regimens, 10.1111/j.1572-0241.1999.01200.x
  8. Shale M. J., Riley S. A., Studies of compliance with delayed-release mesalazine therapy in patients with inflammatory bowel disease, 10.1046/j.1365-2036.2003.01648.x
  9. Janke Karl-Heinz, Klump Bodo, Gregor Michael, Meisner Christoph, Haeuser Winfried, Determinants of Life Satisfaction in Inflammatory Bowel Disease : , 10.1097/01.mib.0000160809.38611.f7
  10. Han Seong Won, McColl Elaine, Barton John Roger, James Peter, Steen Ian Nicholas, Welfare Mark Richard, Predictors of Quality of Life in Ulcerative Colitis. : The Importance of Symptoms and Illness Representations, 10.1097/00054725-200501000-00004
  11. Prantera Cosimo, Viscido Angelo, Biancone Livia, Francavilla Antonio, Giglio Lucio, Campieri Massimo, A New Oral Delivery System for 5-ASA: Preliminary Clinical Findings for MMX : , 10.1097/01.mib.0000158386.25660.1e
  12. Mohammadi-Samani Soliman, Bahri-Najafi Rahim, Yousefi Golamhosein, Formulation and in vitro evaluation of prednisolone buccoadhesive tablets, 10.1016/j.farmac.2005.01.009
  13. Ali J, Pharmazie, 53, 329 (1998)
  14. Levine Douglas S., Riff Dennis S., Pruitt Ronald, Wruble Lawrence, Koval George, Sales David, Bell John K., Johnson Lorin K., A randomized, double blind, dose-response comparison of balsalazide (6.75 g), balsalazide (2.25 g), and mesalamine (2.4 g) in the treatment of active, mild-to-moderate ulcerative colitis1, 10.1111/j.1572-0241.2002.05781.x
  15. Pruitt RE, Aliment Pharmacol Ther, 97, 3078 (2002)
  16. Schroeder KW, N Engl J Med, 317, 1625 (1987)
  17. Kane Sunanda, Huo Dezheng, Magnanti Kalyani, A pilot feasibility study of once daily versus conventional dosing mesalamine for maintenance of ulcerative colitis, 10.1053/cgh.2003.50025
  18. Hanauer S, Gastroenterology, 128, A-75 (2005)
  19. Frieri G., Pimpo M., Galletti B., Palumbo G., Corrao G., Latella G., Chiaramonte M., Caprilli R., Long-term oral plus topical mesalazine in frequently relapsing ulcerative colitis, 10.1016/j.dld.2004.09.017